Global Claudin 18.2-Targeted Immunotherapy Landscape Analysis Report 2023: Potential Approvals and Market Launches Expected During the Course of 2024

/PRNewswire/ -- The "Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An...

Related Keywords

Shanghai ,China ,Qilu ,Gansu ,Dublin ,Ireland ,Japan ,Nanjing ,Jiangsu ,Longyao ,Chinese ,Junshi Biosciences ,Laura Wood ,Innovent Biologics ,Sichuan Kelun ,Bispecific Immuno ,Kaedi Biotherapeutics ,Genor Biopharma ,Triumvira Immunologcics ,Astellas Pharma ,European Union ,Clinical Development ,Chinese Biopharmaceutical Companies ,Technology Scientific ,Transcenta Holding ,Development Stage ,Company Profiles ,Sparx Group ,Other Biopharmaceutical Companies Outside Of China ,Jiangsu Hengrui Pharmaceuticals ,Zai Lab ,Bristol Myers Squibb ,Major Biopharmaceutical Companies Outside Of China ,E St Office Hours Call ,Astrazeneca ,Office Hours Call ,Landscape Analysis ,Drug Modalities ,Business Opportunities ,T Cell Engaging ,Targeted Bispecific Immuno Oncology ,Big Pharma ,Scientific Officer ,Topics Covered ,Biopharmaceutical Companies Outside ,Biopharmaceutical Companies ,Targeted Naked Monoclonal ,Antibody Drug Conjugates ,Chimeric Antigen Receptort Cells ,Bispecifict Cell Engaging ,Bispecific Immuno Oncology ,Antigen Receptor ,Free Call ,Hours Call ,Research And Markets ,